Bayer is highlighting new and expanded patient throughput and workflow features in its artificial intelligence (AI) portfolio at the RSNA meeting in Chicago.
Bayer is showcasing its next-generation CT technology, MEDRAD Centargo CT Injection system, which is pending clearance by the U.S. Food and Drug Administration (FDA), the company said.
It is also highlighting details on its recently launched Calantic SPARK program, an accelerator program for medical imaging app developers that supports them to bring new products to market. The program will initially focus on North America and Europe.
In addition, Bayer announced collaboration agreements with app developers Quantib, ClariPi, and EXINI Diagnostics which it hopes will expand the capacity of its medical imaging platform Calantic Digital Solutions. The new collaboration agreements broaden options for thoracic and neurological diseases on the Calantic platform by including tools to aid in breast and prostate imaging.
